Craig H. Reynolds

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology

Nasser H. Hanna, Marcus A. Neubauer, Constantin T. Yiannoutsos et al. · Journal of Clinical Oncology · 2008 · 496 citations

Medicine, Oncology, Radiation Oncology +15

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Jyoti D. Patel, Mark A. Socinski, Edward B. Garon et al. · Journal of Clinical Oncology · 2013 · 374 citations · Full text

Medicine, Oncology, Pharmacology +13

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: CheckMate 153

David Waterhouse, Edward B. Garon, Jason C. Chandler et al. · Journal of Clinical Oncology · 2020 · 240 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

David R. Spigel, Craig H. Reynolds, David Waterhouse et al. · Journal of Thoracic Oncology · 2018 · 227 citations · Full text

Medicine, Oncology, Pharmacology +15